首页 | 本学科首页   官方微博 | 高级检索  
     


Effect of Astragalus membranaceus and Angelica sinensis combined with Enalapril in rats with obstructive uropathy
Authors:Ken Wojcikowski  Hans Wohlmuth  David W. Johnson  Glenda Gobe
Affiliation:1. Molecular and Cellular Pathology, School of Medicine, University of Queensland, Brisbane, Queensland, Australia;2. Department of Natural and Complementary Medicine, Southern Cross University, Lismore, NSW, Australia;3. Medicinal Plant Herbarium, Southern Cross University, Lismore, NSW, Australia;4. Department of Renal Medicine, University of Queensland at Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland, Australia
Abstract:ACE inhibitors (ACEi) reduce renal tubulointerstitial fibrosis but are not completely effective. Combined extract of Astragalus membranaceus and Angelica sinensis (A&A) is a traditional antifibrotic agent in China. The present investigation aimed to determine whether an ACEi (Enalapril) and A&A together have a better antifibrotic effect in unilateral ureteral obstruction (UUO) than monotherapy with either agent. Male Sprague‐Dawley rats (N = 4 per group) had either sham operation or UUO alone, with A&A (combined aqueous and ethanol extract equivalent to 2.1 g dried herbs), with Enalapril (in drinking water at 200 mg/mL) or with both treatments. Kidney and liver were collected for protein extraction or fixed for histologic stains, immunohistochemistry (IHC), microscopy. Enalapril or A&A individually were antifibrotic. Transforming growth factor‐β1, fibroblast activation, collagen deposition, macrophage accumulation and tubular cell apoptosis were all decreased. The combination of the two drugs was significantly more effective than Enalapril alone in reducing tumor necrosis factor‐α, collagen accumulation, activation of fibroblasts, and tubular cell apoptosis. In conclusion, Enalapril with A&A significantly decreased tubulointerstitial fibrosis to a greater extent than treatment with Enalapril alone. Further studies focusing on the isolation of the active constituents of A&A and the clinical application of the combination of ACEi plus A&A are warranted to determine the value of this treatment in humans. Copyright © 2009 John Wiley & Sons, Ltd.
Keywords:Chronic kidney disease  Renal fibrosis  A&A  Astragalus  UUO  Transcribing growth factor beta‐1
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号